Mateos M-V, Bringhen S, Richardson PG, Lahuerta JJ, Larocca A, Oriol A, Boccadoro M, García-Sanz R, Di Raimondo F, Esseltine D-L, van de Velde H, Desai A, Londhe A, San Miguel JF, Palumbo A. Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. Haematologica 2014; 99(6):1114-1122; https://doi.org/10.3324/haematol.2013.099341.